9 completed, 5 terminated, 4 unknown, 3 withdrawn. 22 Phase 2, 5 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 9, Terminated 5, Unknown 4, Withdrawn 3, Suspended 1 |
| Phase 3 | 5 | Completed 3, Unknown 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
Follow Complex Regional Pain Syndromes: new trials by email Literature Review of Complex Regional Pain Syndromes trials Research Report on Complex Regional Pain Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ketamine and Midazolam Infusions for CRPS: Feasibility Study Ketamine, Midazolam, Normal Saline - Complex Regional Pain Syndromes | Phase 2 | Withdrawn | Stanford University | 2099-01-01 | 2024-11-22 | |
| Ketamine HCl Prolonged Release Oral Tablets for CRPS 80mg/day Ketamine HCl Prolonged Release, 160mg/day Ketamine HCl Prolonged Release - Complex Regional Pain Syndromes | Phase 2 | Suspended | University of Southern California | 65 | 2027-01-01 | 2026-07-27 |
| Peripheral Nerve Injections for CRPS Triamcinolone Acetonide 40mg/mL, Saline Injection, Bupivacaine - Complex Regional Pain Syndromes | Phase 2 | Unknown | Ottawa Hospital Research Institute | 50 | 2024-05-30 | 2024-09-19 |
| Effectiveness of Ketamine Administered by Mesotherapy in Complex Regional Pain Syndrome Type 1 (CRPS1) LIDOCAINE 20 mg, LIDOCAINE 20 mg + KETAMINE 20 mg, LIDOCAINE 20 mg + KETAMINE 40 mg - Neuropathic Pain, Complex Regional Pain Syndrome Type 1 | Phase 2 / Phase 3 | Completed | Hospices Civils de Lyon | 31 | 2021-11-05 | 2026-08-10 |
| Study of TAK-935 as an Adjunctive Therapy in Adult Participants With Complex Regional Pain Syndrome (CRPS) Soticlestat, Placebo - Complex Regional Pain Syndrome | Phase 2 | Completed | Millennium Pharmaceuticals, Inc. | 24 | 2019-07-23 | 2026-09-14 |
| Adipose Stem/Stromal Cells in RSD, CRPS, Fibromyalgia Lipoaspiration, ADcSVF isolation, Normal Saline IV - RSD (Reflex Sympathetic Dystrophy), CRPS - Complex Regional Pain Syndrome Type I | Phase 1 / Phase 2 | Withdrawn | Healeon Medical Inc | 2018-12-15 | 2021-02-16 | |
| Novel Treatment Option for Neuropathic Pain Cetuximab, Placebo - Neuralgia, Complex Regional Pain Syndromes | Phase 2 | Completed | Sorlandet Hospital HF | 15 | 2015-10-01 | 2016-11-08 |
| Efficacy and Safety of Intravenous Neridronic Acid in CRPS-I Placebo, Neridronic acid 62.5 mg - Complex Regional Pain Syndrome, Type I | Phase 2 / Phase 3 | Completed | GrĂ¼nenthal GmbH | 459 | 2015-04-01 | 2018-05-09 |
| Randomized Controlled Trial of Ketamine Infusion With Continuous Epidural Infusion for Treatment of Complex Regional Pain Syndrome Ketamine Infusion + Epidural Infusion, Control Group + Epidural infusion, Ketamine Booster Infusion - Complex Regional Pain Syndrome | Phase 2 | Terminated | Hospital for Special Surgery, New York | 3 | 2014-03-24 | 2018-01-31 |
| The Use of Zoledronic Acid to Complex Regional Pain Syndrome Zoledronic acid, Placebo - Complex Regional Pain Syndromes | Phase 2 | Unknown | University of Sao Paulo General Hospital | 40 | 2013-12-01 | 2013-02-11 |
| Acupuncture for Post-stroke Shoulder-hand Syndrome rehabilitation, Acupuncture - Shoulder-hand Syndrome | Phase 2 / Phase 3 | Unknown | Zouqin Huang | 90 | 2013-10-01 | 2013-12-13 |
| Efficacy of Etoricoxib on Peripheral Hyperalgesia Etoricoxib, placebo - Causalgia, Polyneuropathy | Phase 2 | Terminated | Ruhr University of Bochum | 9 | 2011-02-01 | 2012-08-24 |
| Effects of Vaporized Marijuana on Neuropathic Pain Mild dose cannabis, Low dose cannabis, Cannabis - Neuropathic Pain, Reflex Sympathetic Dystrophy | Phase 1 / Phase 2 | Completed | University of California, Davis | 44 | 2009-12-01 | 2018-01-31 |
| Pain Exposure Physical Therapy (PEPT) Versus CBO in Patients With Complex Regional Pain Syndrome Type I (CRPS-1) PEPT, CBO standard - Complex Regional Pain Syndrome, Type I | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 62 | 2009-01-01 | 2013-07-24 |
| Safety and Efficacy Study of Ethosuximide for the Treatment of Complex Regional Pain Syndrome (CRPS) Placebo, Ethosuximide - Complex Regional Pain Syndromes | Phase 2 | Terminated | McGill University Health Centre/Research Institute of the McGill University Health Centre | 4 | 2008-09-01 | 2011-05-13 |
| Double Blind Placebo Controlled Study of Outpatient Intravenous Ketamine for the Treatment of CRPS Ketamine, IV NSS, Normal Saline - Complex Regional Pain Syndrome | Phase 2 | Completed | Drexel University College of Medicine | 40 | 2006-09-01 | 2010-06-17 |
| Effect of Delta-9-Tetrahydrocannabinol on the Prevention of Chronic Pain in Patients With Acute CRPS (ETIC-Study) Delta9-Tetrahydrocannabinol - Complex Regional Pain Syndromes, CRPS | Phase 2 | Unknown | Ludwig-Maximilians - University of Munich | 100 | 2006-09-01 | 2008-06-30 |
| Transcranial Magnetic Stimulation (TMS) Effects on Pain Perception laboratory pain assessment, transcranial magnetic stimulation - Pain, Trigeminal Neuralgia | Phase 2 / Phase 3 | Withdrawn | Medical University of South Carolina | 2006-07-01 | 2012-04-30 | |
| Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1 lenalidomide, Placebo - Complex Regional Pain Syndrome, Type I | Phase 2 | Terminated | Celgene Corporation | 184 | 2005-02-01 | 2013-08-28 |
| Clonidine Versus Adenosine to Treat Neuropathic Pain clonidine, adenosine, placebo - Pain | Phase 2 | Completed | Wake Forest University Health Sciences | 24 | 2004-08-01 | 2018-09-10 |
Showing 20 of 22. Sign in to see all of them.
Reflex Sympathetic Dystrophy (9) · Neuralgia (7) · Pain (5) · Chronic Pain (4) · Agnosia (2) · Causalgia (2) · Neuralgia, Postherpetic (2) · Bronchiolitis Obliterans Syndrome (1) · Fibromyalgia (1) · Marijuana Abuse (1) · Multiple Sclerosis (1) · Peripheral Nerve Injuries (1) · Peripheral Nervous System Diseases (1) · Polyneuropathies (1)
Autonomic Nervous System Diseases (22) · Nervous System Diseases (22) · Neuromuscular Diseases (22) · Peripheral Nervous System Diseases (21) · Neurologic Manifestations (13) · Pathological Conditions, Signs and Symptoms (13) · Signs and Symptoms (13) · Pain (7) · Immune System Diseases (2) · Mental Disorders (2) · Neurobehavioral Manifestations (2) · Perceptual Disorders (2) · Trauma, Nervous System (2) · Wounds and Injuries (2)
Ketamine (4) · Sodium Chloride (3) · Lenalidomide (2) · Saline Solution (2) · 1,10-phenanthroline-platinum(II)-ethylenediamine (1) · 6-amino-1-hydroxyhexane-1,1-diphosphonate (1) · Acupuncture Therapy (1) · Adenosine (1) · Bupivacaine (1) · Cetuximab (1) · Clonidine (1) · Control Groups (1) · Dronabinol (1) · Ethosuximide (1) · Etoricoxib (1)
Celgene Corporation (2) · Drexel University College of Medicine (1) · GrĂ¼nenthal GmbH (1) · Healeon Medical Inc (1) · Hospices Civils de Lyon (1) · Hospital for Special Surgery, New York (1) · Ludwig-Maximilians - University of Munich (1) · McGill University Health Centre/Research Institute of the McGill University Health Centre (1) · Medical University of South Carolina (1) · Millennium Pharmaceuticals, Inc. (1) · National Institute of Nursing Research (NINR) (1) · Ottawa Hospital Research Institute (1) · Radboud University Medical Center (1) · Ruhr University of Bochum (1) · Sorlandet Hospital HF (1)
United States (12) · Germany (3) · Canada (2) · United Kingdom (2) · Brazil (1) · China (1) · France (1) · Honduras (1) · Netherlands (1) · Norway (1)
Barth L Wilsey, MD (1) · Christian Kersten, MD PhD (1) · Christoph Maier, Dr.med (1) · Daniel I Richman, MD (1) · Donald C Manning, MD, PhD (1) · Donald Manning, MD, PhD (1) · Glenn C Terry, MD (1) · Huang Zouqin, Dcctor (1) · James C. Eisenach, M.D. (1) · Jeffrey J. Borckardt, Ph.D. (1) · Leorey Saligan, PhD, CRNP (1) · Linamara R. Battistella, PHD (1) · Mark A Ware, MD (1)
PMID 22515496, PMID 25283471, PMID 25919011, PMID 26628523, PMID 31106835, PMID 36538782, PMID 42421175
2009 (1), 2014 (1), 2015 (1), K23NS050485 (1), P01NS041386 (1)